Search research articles
Contact Us
Filters
Showing results (381-390 of 403) with videos related to
Page
of 41
Sort By:
Lancet (London, England)
|
August 23, 2011
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial
Gilles Montalescot, Uwe Zeymer, Johanne Silvain, et al.
Circulation
|
November 25, 2016
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy
C Michael Gibson, Duane S Pinto, Gerald Chi, et al.
American Heart Journal
|
August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
John L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
European Heart Journal
|
October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial
Giulia Magnani, Robert F Storey, Gabriel Steg, et al.
Journal of the American College of Cardiology
|
April 6, 2016
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
Marc P Bonaca, Deepak L Bhatt, Robert F Storey, et al.
European Heart Journal
|
October 23, 2015
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54
Marc P Bonaca, Deepak L Bhatt, P Gabriel Steg, et al.
Thyroid : Official Journal of the American Thyroid Association
|
February 26, 2024
<i>RAS</i>-Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active Surveillance
Hannah J Sfreddo, Elizabeth S Koh, Karena Zhao, et al.
JAMA Cardiology
|
July 21, 2016
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial
Marc P Bonaca, Deepak L Bhatt, Ton Oude Ophuis, et al.
Circulation. Genomic and Precision Medicine
|
January 12, 2021
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease
Nicholas A Marston, Giorgio E M Melloni, Yared Gurmu, et al.
JAMA Internal Medicine
|
October 7, 2021
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial
Alex C Spyropoulos, Mark Goldin, Dimitrios Giannis, et al.
Page
of 41
Search research articles
Search
Showing results (381-390 of 403) with videos related to
Sort By:
Page
of 41
Lancet (London, England)
|
August 23, 2011
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial
Gilles Montalescot, Uwe Zeymer, Johanne Silvain, et al.
Circulation
|
November 25, 2016
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy
C Michael Gibson, Duane S Pinto, Gerald Chi, et al.
American Heart Journal
|
August 17, 2004
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library
John L Petersen, Kenneth W Mahaffey, Richard C Becker, et al.
European Heart Journal
|
October 8, 2015
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial
Giulia Magnani, Robert F Storey, Gabriel Steg, et al.
Journal of the American College of Cardiology
|
April 6, 2016
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
Marc P Bonaca, Deepak L Bhatt, Robert F Storey, et al.
European Heart Journal
|
October 23, 2015
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54
Marc P Bonaca, Deepak L Bhatt, P Gabriel Steg, et al.
Thyroid : Official Journal of the American Thyroid Association
|
February 26, 2024
<i>RAS</i>-Mutated Cytologically Indeterminate Thyroid Nodules: Prevalence of Malignancy and Behavior Under Active Surveillance
Hannah J Sfreddo, Elizabeth S Koh, Karena Zhao, et al.
JAMA Cardiology
|
July 21, 2016
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial
Marc P Bonaca, Deepak L Bhatt, Ton Oude Ophuis, et al.
Circulation. Genomic and Precision Medicine
|
January 12, 2021
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease
Nicholas A Marston, Giorgio E M Melloni, Yared Gurmu, et al.
JAMA Internal Medicine
|
October 7, 2021
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial
Alex C Spyropoulos, Mark Goldin, Dimitrios Giannis, et al.
Page
of 41